Canaccord Genuity Maintains Buy on CRISPR Therapeutics, Raises Price Target to $160
Canaccord Genuity analyst Arlinda Lee maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $151 to $160.
Cathie Wood’s ARK Invest Posts Fund Purchases For Thursday, Aug. 12, 2021: DKNG, ETSY, PLTR, SMFR, ZY, CRSP, SDGR, VCYT, TSP, SGFY, BLI, VUZI, MKFG, LPSN
DraftKings (DKNG) - 55,100 Shares
Etsy (ETSY) - 27,834
Palantir Technologies (PLTR) - 5,602,325
Sema4 (SMFR) - 183,204
Zymergen (ZY) - 8,322
CRISPR Therapeutics (CRSP) - 25,000
Schrodinger (SDGR) -
Unusual Options Activity Insight: CRISPR Therapeutics
CRISPR Therapeutics (NASDAQ:CRSP) shares experienced unusual options activity on Thursday. The stock price moved up to $128.88 following the option alert.
Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $171
Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $175 to $171.
Why CRISPR Therapeutics’ Stock Is Trading Higher Today
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher after the company reported Q2 earnings per share results of $9.44, up from $(1.30) year-over-year.
CRISPR Therapeutics Q2 EPS $9.44 Up From $(1.30) YoY
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly earnings of $9.44 per share. This is a 826.15 percent increase over losses of $(1.30) per share from the same period last year.
Alzheimer’s Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What’s Next?
For most of the past year, just a handful of companies carried the biotech sector, thanks to their quick responses to the COVID-19 pandemic.
‘Halftime Report’ Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond
Amy Raskin said on CNBC's "Fast Money Halftime Report" that she would hold Crispr Therapeutics AG (NASDAQ: CRSP).
Why Gene Editing Stocks Are Trading Higher Again Today
Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its investigational CRISPR therapy.
61 Biggest Movers From Yesterday
Gainers
Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.